Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion type Assertion NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_head.
- NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion description "[This personalization of NSCLC therapy is typified by the dramatic response rates seen in EGFR mutant NSCLC when treated with targeted tyrosine kinase inhibitor therapy and in ALK translocation-driven NSCLC when treated with ALK inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_provenance.
- NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion evidence source_evidence_literature NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_provenance.
- NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion SIO_000772 24258572 NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_provenance.
- NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion wasDerivedFrom befree-2016 NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_provenance.
- NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_assertion wasGeneratedBy ECO_0000203 NP1130001.RA8wiGWgem1WCqbfMSZP-g9IWHFzwn9EXmwhyLUih01Wc130_provenance.